Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
115 hedge funds and large institutions have $380M invested in Progenics Pharmaceuticals Inc in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.
71% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 17
53% more capital invested
Capital invested by funds: $249M → $380M (+$131M)
44% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.02M
11% more funds holding
Funds holding: 104 → 115 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$5.71M |
| 2 |
Goldman Sachs
New York
|
+$5.38M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.36M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$3.29M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$12.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.6M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.08M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.93M |
| 5 |
RA
Royce & Associates
New York
|
-$1.12M |
PGNX Hedge Fund Activity: Q3 2016 in Review
115 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2016, worth a combined $380M — up 53% from $249M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PGNX positions and 17 closed out — a net gain of 12 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was Phocas Financial Corp, adding an estimated $5.71M. The largest seller was Tudor Investment Corp, cutting an estimated $12.4M.
- 115 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2016, up from 104 in Q2 2016.
- Funds reported $380M of Progenics Pharmaceuticals Inc stock for Q3 2016, up 53% quarter-over-quarter.
- 29 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2016 and 17 closed out, a net change of +12 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2016 was Phocas Financial Corp, an estimated $5.71M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2016 was Tudor Investment Corp, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2016.